黑料网

Morphine; Pharmacokinetics; Absorption; distribution; Metabolism; Liver metabolism; Glucuronidation

Introduction

Metabolism plays a significant role in the pharmacokinetics of morphine. The liver primarily metabolizes morphine through glucuronidation and sulfation processes, forming metabolites such as morphine-3-glucuronide and morphine-6-glucuronide. These metabolites can contribute to the overall analgesic activity and potential side effects of morphine. Morphine, a powerful opioid analgesic, has been widely used for many years in the management of severe pain, particularly in cases where other analgesics have proven ineffective. Its effectiveness and potency make it a valuable tool in pain management, but its pharmacokinetic properties must be well understood to ensure safe and optimal therapeutic use [1].

Analgesia is produced when the k receptors are activated by morphine, which is an agonist. Through the opioid receptors, morphinelike agonists mediate their effects, resulting in sedation, euphoria, and respiratory depression. Morphine inhibits transmission from primary afferent nociceptors to dorsal horn sensory projection cells, activates pain-modulating neurons' signaling to the spinal cord, and blocks the transmission of nociceptive signals. The degree of analgesia increases with increasing doses until an anesthetic level is reached. Morphine's limited lipid solubility and slow rate of penetration through the bloodbrain barrier contribute to its relatively slow onset of analgesia after intravenous administration (6-30 min). Morphine also undergoes a significant amount of first-pass metabolism; To achieve the same degree of analgesia, oral doses must therefore be six times greater than parenteral doses 2. However, adults' short-term elimination half-life of 3-4 hours limits analgesia duration [2].

Pharmacokinetics refers to the study of the absorption, distribution, metabolism, and elimination of drugs within the body. These processes determine how a drug behaves in the body, including its onset and duration of action, as well as the potential for accumulation and toxicity. Understanding the pharmacokinetics of morphine is crucial for healthcare professionals to make informed decisions regarding dosage, administration routes, and monitoring strategies. Morphine can be administered via various routes, including oral, intravenous, intramuscular, and transdermal routes. The choice of administration route can significantly affect the pharmacokinetic profile of morphine, including its bioavailability and onset of action. Factors such as the formulation and individual patient characteristics can also influence the rate and extent of absorption [3].

Pharmacokinetics metabolism

Metabolism plays a significant role in morphine pharmacokinetics. The liver is the primary site of morphine metabolism, where it undergoes glucuronidation and sulfation processes to form metabolites such as morphine-3-glucuronide and morphine-6-glucuronide. These metabolites can contribute to the overall pharmacological effects and potential side effects of morphine. Elimination of morphine and its metabolites primarily occurs via renal excretion. Renal function plays a crucial role in the clearance of morphine, and impaired kidney function can lead to the accumulation of active metabolites, increasing the risk of adverse effects. Monitoring renal function and adjusting dosage regimens accordingly is important to ensure safe and effective use of morphine. Understanding the factors that can influence morphine pharmacokinetics, such as age, hepatic function, renal function, genetics, and concurrent use of other medications, is essential for tailoring therapy to individual patients. By considering these factors, healthcare professionals can optimize morphine dosing regimens and minimize the risk of adverse effects [4].

Materials and Methods

Modeling absorption-related physiological changes caused by aging

The sections that follow provide a summary of the aging-related physiological and anatomical changes in the GI tract for important processes that affect absorption. The commercial and open-source software packages that were discussed earlier are also described in terms of the PBPK platforms' capacity to accommodate these modifications. Since OSP is the only open-source software, model parameters for Simcyp and GastroPlus were derived from publications or responses to a questionnaire that was distributed to representatives of all three software providers regarding the parameterization of absorption in their respective geriatric models [5].

Oral cavity and swallowing capacity

With the exception of lactate dehydrogenase, advanced age is associated with lower salivary flow rates, which are primarily caused by a decrease in the amount of water present in salivary components like potassium, calcium, and amylase. Dysphagia, or difficulty swallowing, and xerostomia, or dry mouth, both of which are frequently linked to drug use, may both be exacerbated by this. Changes in saliva composition have been overlooked because of the short residence time in the mouth because most major PBPK platforms are optimized for swallowable dosage forms. However, the majority of these platforms permit changes in flow rates. The majority of the current modeling platforms are able to define the pH of saliva once this data becomes available, despite the fact that there has been little to no research to date regarding any age-related changes in salivary pH [6].

Drug cooperations as a result of polypharmacy in more established individuals

More seasoned individuals are troubled with high paces of multimorbidity bringing about polypharmacy and in this manner, a more serious gamble for drug communications (DDIs). When co-medications bind to these species, DDIs can occur during the absorption phase through a variety of mechanisms, including the induction or inhibition of transporters and drug-metabolizing enzymes (DMEs). OATP1B1, P-glycoprotein, CYP3A4, and CYP2C9 are a few of the most important transporters and enzymes that are expressed in the small intestine and can have an impact on oral drug absorption. Through inhibition, the substantial overlap between P-gp and CYP3A4 substrates can result in a significant increase in drug bioavailability. Drug-induced physiological changes in the gastrointestinal tract can also play a role in DDIs, as described in the following section: Intestinal movability and emptying of the stomach [7].

Modeling inferences

Regulatory agencies have long advocated for greater older participant participation in clinical trials, such as the 1993 ICH E7 recommendation to enroll at least 100 people over the age of 65 if they are a target group for the drug. In spite of this, avoidance models, for example, nonappearance of comorbidity or polypharmacy can in any case obstruct enrolment, regardless of whether as far as possible is brought up in the clinical examinations. However, a rise to 47 percent is anticipated by relaxing only the exclusions for organ conditions; however, this also assumes that a significant number of people are willing to participate. In point of fact, there are a number of factors that cast doubt on this assumption, including a limited capacity to comprehend and provide informed consent, misconceptions regarding clinical studies and patient rights, fear or a lack of trust; A lot of people in this target group might think twice about enrolling [8].

Result and Discussion

The results of studies on morphine pharmacokinetics have provided valuable information on various aspects of the drug's behavior within the body. These studies have investigated parameters such as absorption, distribution, metabolism, and elimination, shedding light on how morphine is processed and eliminated from the body. They have also explored factors that can influence these processes, such as different routes of administration, patient characteristics, and concurrent medications.

Absorption studies have examined the bioavailability and rate of absorption of morphine through different routes, providing information on the optimal administration method for achieving the desired therapeutic effects. These studies have shown that intravenous administration yields the highest bioavailability and rapid onset of action, while oral administration may have lower bioavailability due to first-pass metabolism. Distribution studies have investigated the distribution patterns of morphine within the body, including its ability to cross the blood-brain barrier and reach its site of action in the central nervous system. These studies have contributed to understanding the concentration of morphine in various tissues and organs, helping to determine the duration of action and potential for accumulation [9].

Metabolism studies have focused on the metabolic pathways of morphine, particularly glucuronidation and sulfation processes in the liver. These studies have identified the major metabolites of morphine, such as morphine-3-glucuronide and morphine-6-glucuronide, and their contribution to the overall pharmacological effects and potential side effects of morphine. Elimination studies have explored the renal excretion of morphine and its metabolites. They have investigated the influence of renal function on morphine clearance and the potential for accumulation in patients with impaired kidney function. These studies have provided insights into the importance of monitoring renal function and adjusting dosage regimens to ensure safe and effective use of morphine.

The discussion surrounding morphine pharmacokinetics can revolve around several key points. These include:

Optimal route of administration: The results of absorption studies can inform discussions on the most effective and appropriate route of administration for different clinical scenarios, taking into account factors such as onset of action, bioavailability, and patient preferences.

Individual variability: The pharmacokinetics of morphine can vary among individuals due to factors such as age, hepatic and renal function, genetics, and concurrent medication use. Discussing these sources of variability can highlight the need for individualized dosing and monitoring strategies.

Metabolism and active metabolites: The formation of active metabolites, such as morphine-6-glucuronide, can contribute to the overall pharmacological effects and potential side effects of morphine. Discussions may revolve around the clinical implications of these metabolites and their relevance in different patient populations [10].

Renal impairment and dose adjustments: The impact of renal function on the elimination of morphine and its metabolites is an important consideration in patients with impaired kidney function. Discussing appropriate dose adjustments and monitoring strategies for this patient population can help ensure safe and effective use of morphine.

Drug interactions: Morphine pharmacokinetics can be influenced by concurrent use of other medications, such as inhibitors or inducers of hepatic enzymes. Discussing potential drug interactions and their implications on morphine therapy can aid in identifying and managing such interactions.

Conclusion

Absorption: Different routes of administration affect the bioavailability and onset of action of morphine. Intravenous administration yields the highest bioavailability, while oral administration may have lower bioavailability due to first-pass metabolism.

Distribution: Morphine distributes extensively throughout the body, crossing the blood-brain barrier to exert its analgesic effects. Distribution is influenced by factors such as plasma protein binding and tissue permeability.

Metabolism: Morphine is primarily metabolized in the liver through glucuronidation and sulfation processes, forming metabolites such as morphine-3-glucuronide and morphine-6-glucuronide. These metabolites contribute to the overall pharmacological effects and potential side effects of morphine. Morphine and its metabolites are primarily eliminated via renal excretion.

Acknowledgement

None

1. Cheng YW, Chiu MJ, Chen YF, Cheng TW, Lai YM, et al. (2020) . Alzheimers Res Ther 12:1-10.

, ,

2. Li F, Maag H, Alfredson T (2008) . J Pharm Sci 7:1109-1134.

, ,

3. Sinko PJ, Balimane PV (1998) . Bio pharm Drug Dispos 19:209-217.

, ,

4. Goffredo M, Mass K, Parks EJ, Wagner DA, Mcclure EA, et al. (2016) J Clin. Endocrinol Metab 101:4367-4476.

, ,

5. Puymirat E, Lamhaut L, Bonnet N, Aissaoui N, Henry P, et al. (2016) . Eur Heart J 37:1063-1071.

, ,

6. Alam P , Chaturvedi SK, Siddiqi MK, Rajpoot RK, Ajmal MR, et al. (2016) . Sci Rep 6:26759.

, ,

7. Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, et al. (1998)  . Pharm Res 15:1154-1159.

, ,

8. Yao SY, Ng AM, Vickers MF, Sundaram M, Cass CE, et al.  (2002) . J Biol Chem 277:24938-24948.

, ,

9. Toshiya K, Ken-Ichi I (2003) Drug Metab Pharmacokinet 18:1-15.

 ,

10. Flint OP (1994) Toxicol In Vitro 8:677-683.

, ,